Heron Therapeutics Inc (NASDAQ:HRTX) Expected to Post Earnings of -$0.60 Per Share

Equities analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will announce ($0.60) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Heron Therapeutics’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.67). Heron Therapeutics posted earnings per share of ($0.63) in the same quarter last year, which would indicate a positive year-over-year growth rate of 4.8%. The company is expected to announce its next quarterly earnings results on Monday, August 3rd.

According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($2.33) per share for the current financial year, with EPS estimates ranging from ($2.77) to ($1.41). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.92) per share, with EPS estimates ranging from ($2.00) to $0.19. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.08. The firm had revenue of $25.40 million during the quarter, compared to the consensus estimate of $21.23 million. Heron Therapeutics had a negative return on equity of 56.85% and a negative net margin of 138.31%. The company’s revenue was down 19.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.80) EPS.

A number of research firms have recently commented on HRTX. ValuEngine cut Heron Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 4th. Cantor Fitzgerald reissued a “buy” rating and set a $41.00 price target on shares of Heron Therapeutics in a report on Thursday, February 20th. FIX assumed coverage on Heron Therapeutics in a report on Monday, May 18th. They set an “add” rating for the company. BidaskClub raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $29.00 target price on shares of Heron Therapeutics in a report on Wednesday, May 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. Heron Therapeutics has a consensus rating of “Buy” and a consensus price target of $40.75.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. X Square Capital LLC bought a new stake in shares of Heron Therapeutics in the 1st quarter valued at about $117,000. Orbimed Advisors LLC bought a new stake in shares of Heron Therapeutics in the 1st quarter valued at about $6,309,000. Engineers Gate Manager LP grew its position in shares of Heron Therapeutics by 217.7% in the 1st quarter. Engineers Gate Manager LP now owns 43,236 shares of the biotechnology company’s stock valued at $508,000 after buying an additional 29,628 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Heron Therapeutics by 165.5% in the 1st quarter. Squarepoint Ops LLC now owns 211,531 shares of the biotechnology company’s stock valued at $2,483,000 after buying an additional 131,851 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Heron Therapeutics by 8.1% in the 1st quarter. Invesco Ltd. now owns 283,494 shares of the biotechnology company’s stock valued at $3,329,000 after buying an additional 21,337 shares during the last quarter.

Shares of Heron Therapeutics stock traded up $1.19 during trading on Friday, reaching $18.24. 1,347,714 shares of the company’s stock were exchanged, compared to its average volume of 1,005,696. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.53 and a quick ratio of 4.17. Heron Therapeutics has a 1-year low of $9.60 and a 1-year high of $26.81. The firm’s 50-day moving average price is $14.39 and its 200 day moving average price is $19.35.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: Balanced Fund

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.